Oragenics Inc. · AMEX:OGEN
Oragenics — Investor Presentation (April 2022)
11 slides from Oragenics's investor presentation, Apr 19, 2022
Slide 1: April 18-22, 2022
April 18-22, 2022 NYSE: OGEN
Slide 2: Oragenics Summary
Oragenics Summary Lead Asset: NT-CoV2-1 + Licensed from NIH — two-proline substitution of SARS-CoV-2 spike protein NT-CoV2-1 Intranasal Vaccine Differentiation and Advantages — Patient-friendly, needle-free administration — May reduce virus transmission at source of infection (mucosal nasopharyngeal
Slide 3: NT-CoV2-1 vaccine platform and development
+ Cell lines 6-8 weeks vs 6-9 months + Sequence -> Ph1 GMP DS in 12 wks + Licensed "2P” substitution used by Pfizer/BioNTech & Nationa inttute of (NIH) Allergy and Moderna Infectious Diseases National Research Council Canada De Resistin-trimerized \ spike protein ~ bh) y » \ Intr | » a, De or = A +
Slide 4: Hamster Study Results - NRC/Oragenics
Hamster Study Results - NRC/Oragenics Intranasal formulation led to high IgG anti-spike protein titers Day 20 Post-Dose 1 Day 35, 2 Weeks Post-Dose 2 10° 105 on we Qn 22 4104. 22 104. si 0889 xf gE og ~o0° Sc 8 § 10° oso § § 10° Pad Boo BE o ze 102 ° 2 § 102 101 pe a 101 Veh. BDX301 BDX301 BDX301 Ve
Slide 5: Hamster Study Results - NRC/Oragenics
udy Results - NRC/Oragenics Intranasal formulation led to undetectable viral loads Lungs Nasal Turbinates 7 ae 7 deve AG z6 3 Q 8 . ES Oo . ES cee adn Ba 28 8 eS4 Agde oa eS £a 3 rN £a 3 $°s $°o B? B? —41 41 o o Veh. BDX301 BDX301 BDX301 Veh. BDX301 BDX301 BDX301 Alone +5ug +45 pg Alone +5yg +15 yg
Slide 6: Hamster Study Results - NRC/Oragenics
udy Results - NRC/Oragenics Intranasal formulation decreased body weight loss 10: Vaccine Formulation *** te PBS 3 BDX301 “© 54g Ag + BDX301 © 15 ug Ag + BDX301 % BW change (Mean + SD) 20+ + 7 T T 1 0 1 2 3 4 5 Days after challenge Efficacy of SmT1v3 and BDX301 formulations against SARS-CoV-2 viral
Slide 7: Intranasal COVID-19 Vaccines
Intranasal. COVID-19 Vaccines Potential benefits of intranasal COVID vaccines + Intranasal vaccines may address limitations of current vaccines — Waning efficacy requiring third (and fourth) doses for new VOCs — Transmission remains a concern due to high nasopharyngeal viral loads * Recent study in
Slide 8: Appendix
Appendix
Slide 9: COVID-19 Vaccine Commercial Analysis
COVID-19 Vaccine Commercial Analysis Intranasal vaccine’ pipeline is limited Intranasal Vaccine Candidates vs. Oragenics’ NT-CoV2-1 Or ion Type Vaccine Type Stage Comments Precision Viralogics/ US biotech/Indian Live chimpanzee adenovirus PRESS Indian-made vaccines unlikely to be Bharat Biotech manu
Slide 10: BDX301 Intranasal Adjuvant
BDX301 Intranasal Adjuvant Positive clinical data for adjuvant family & improved processes Improvements made during GSK ownership to make more soluble | fae improvements to remove Derecere detergent 7 t impurities EXTON > ‘V2 (BDx300) ry Vaceie FomMULsED ey Buierese apaak MIXING WITH ANTIGEN foorres
Slide 11: Oragenics Team
Oragenics. Team * Terry Cochrane - CMC >20 years biopharmaceutical development and GMP manufacturing experience * Tim Cooke PhD, MBA - Commercial >30 years vaccine industry experience at Merck, CEO NovaDigm & Mojave Therapeutics, COO AVANT Immunotherapeutics, National Vaccine Advisory Committee 2015